Aclaris TherapeuticsACRS
About: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Employees: 91
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,175% more call options, than puts
Call options by funds: $51K | Put options by funds: $4K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
1% less funds holding
Funds holding: 97 [Q1] → 96 (-1) [Q2]
3.3% less ownership
Funds ownership: 77.44% [Q1] → 74.13% (-3.3%) [Q2]
15% less capital invested
Capital invested by funds: $68.4M [Q1] → $58.1M (-$10.3M) [Q2]
47% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 38
Research analyst outlook
We haven’t received any recent analyst ratings for ACRS.